Search

Betaxolol

A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

Rose bengal

Its disodium salt in ophthalmic solutions has been used as a diagnostic agent in suspected damage to conjunctival and corneal cells. … A direct cytotoxic effect of Rose bengal on microorganisms and cancer cells has been observed, questioning its potential antitumor actions via intralesional injections.

Larazotide

An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

Talniflumate

Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this … research has now been discontinued [L1402, L1405].

Talactoferrin alfa

It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation. … Lactoferrin, a protein found in breast milk is developed by Agennix.

RUS 3108

RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories. … The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.

MPI-674

AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. … It is developed for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).

Gremubamab

Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).

Reldesemtiv

Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).

Hydrocortisone phosphate